190 related articles for article (PubMed ID: 37899041)
1. Frontline Therapy in Chronic Lymphocytic Leukemia.
Arguello-Tomas M; Albiol N; Moreno C
Acta Haematol; 2024; 147(1):47-59. PubMed ID: 37899041
[TBL] [Abstract][Full Text] [Related]
2. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy.
Moreno C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):33-40. PubMed ID: 33275679
[TBL] [Abstract][Full Text] [Related]
3. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH
Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880
[TBL] [Abstract][Full Text] [Related]
6. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
7. Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
Arguello-Tomas M; Albiol N; Jara P; Garcia-Cadenas I; Redondo S; Esquirol A; Novelli S; Saavedra S; Martino R; Nomdedeu J; Sierra J; Mora A; Moreno C
Leuk Lymphoma; 2023 Oct; 64(10):1655-1661. PubMed ID: 37452739
[TBL] [Abstract][Full Text] [Related]
8. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
9. First line therapy of CLL.
Hallek M
Hematol Oncol; 2023 Jun; 41 Suppl 1():129-135. PubMed ID: 37294974
[TBL] [Abstract][Full Text] [Related]
10. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
11. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
12. Changing landscape of frontline therapy in chronic lymphocytic leukemia.
Bhat SA; Woyach JA
Leuk Lymphoma; 2020 Mar; 61(3):525-535. PubMed ID: 31729270
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A; Bose P; Keating MJ
Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
[TBL] [Abstract][Full Text] [Related]
14. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Markers in the Era of Targeted Therapies.
Kang S; Ahn IE
Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment.
Blachnio K; Grygalewicz B; Woroniecka R; Rygier J; Pienkowska-Grela B; Rymkiewicz G; Kawiak J
Folia Histochem Cytobiol; 2022; 60(3):203-214. PubMed ID: 36045602
[TBL] [Abstract][Full Text] [Related]
18. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia.
Albiol N; Arguello-Tomas M; Moreno C
Curr Opin Oncol; 2021 Nov; 33(6):670-680. PubMed ID: 34474439
[TBL] [Abstract][Full Text] [Related]
19. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Cherng HJ; Jain N
Hematol Oncol Clin North Am; 2021 Aug; 35(4):725-738. PubMed ID: 34174983
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]